ng operating losses and fluctuations
in operating results; capital requirements; regulatory review and approval
of our products; special protocol assessment agreement; the conduct and
timing of clinical trials; commercialization of products; market acceptance
of products; product labeling; concentrated customer base; reliance on
strategic partnerships and collaborations; uncertainties in drug
development; uncertainties regarding intellectual property and other risks
detailed from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements.
CV THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS DATA
(In Thousands, Except Per Share Amounts)
(Unaudited)
Three months ended Year ended
December 31, December 31,
2007 2006 2007 2006
Revenues:
Product sales, net $20,928 $9,029 $66,651 $18,423
Collaborative research 1,474 3,640 16,172 16,923
Co-promotion - - - 1,439
Total revenues 22,402 12,669 82,823 36,785
Costs and expenses (1):
Cost of sales 3,131 1,236 9,689 2,752
Research and
development 19,710 38,102 94,742 135,254
Selling, general and
administrative 32,950 42,956 152,496 177,264
Restructuring charges (11) - 6,763 -
Total costs and expenses 55,780 82,294 263,690 315,270
'/>"/>SOURCE CV Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference2.
Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics3.
The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics4.
CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session5.
Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases6.
Ocera Therapeutics Closes $35.5 Million Series C Financing7.
Amsterdam Molecular Therapeutics Reports Full Year Results 20078.
United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results9.
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 435010.
Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 200811.
PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors